We’re excited to share the release of Self-Registration Options available in myWAPPS 4.0!
This update is designed to encourage healthcare providers (HCPs)—doctors, nurses, and other clinicians—to offer self-registration options to their patients. By enabling patients to register on their own, we can enhance their engagement while ensuring that vital data is accessible within the myWAPPS Dashboard for better treatment decisions.
Why Self-Registration?
Our latest animation video outlines the different ways patients can enroll, making it easier than ever to take an active role in their care.
We encourage you to explore these new features and discuss the benefits of self-registration with your patients.
Follow us on X and YouTube!
Download the myWAPPS app!
We’re excited to introduce a powerful new feature in myWAPPS 4.0—the Bleed Module, designed to make tracking and managing bleeds easier than ever. With faster recording, more detailed tracking, and seamless treatment integration, you and your healthcare provider will have a complete picture of your treatment history.
What’s new in the Bleed Module?
Faster Recording – Log a bleed in seconds.
Detailed Tracking – Document the location, severity, and treatment of each bleed.
Treatment Integration – Record infusion times and dosage for a complete history.
Improved Insights – Give your healthcare provider a real-time overview of your health.
You’ll find the new “Bleeds” section in the main menu, where you can easily log and manage your history. With just a few taps, you can highlight affected areas, track symptoms, and monitor treatments—all in one place.
This is just one of the many ways WAPPS Hemo is making it easier to manage your health while helping doctors provide personalized care.
Stay tuned—more exciting updates are on the way!
Follow us on X and YouTube!
Download the myWAPPS app!
At WAPPS, we believe that communication is at the heart of individualized care for hemophilia. That’s why WAPPS-Hemo uses population PK models to transform patient conversations into practical insights.
Now, we’re taking it a step further. The myWAPPS app is evolving to myWAPPS 4.0, bringing powerful new features designed to enhance patient engagement and ease of use:
To introduce these exciting updates, we’ve created a series of animated videos, starting our first one.
In this first video, you’ll get an overview of myWAPPS 4.0 and its enhanced usability, improved tracking features, and patient-centric tools, all designed to simplify treatment management. You’ll also see how these updates make it easier than ever for patients and healthcare providers to collaborate seamlessly.
This is just the beginning! More videos will follow int he coming weeks, covering each feature in greater detail. Stay tuned for what’s next!
Follow us on X and YouTube!
Download the myWAPPS app!
WAPPS-Hemo welcomes the improved Green Gene F & Green Mono population pharmacokinetic (PK) models to the platform!
We are excited to announce an enhanced version of the Green Gene F and Green Mono models for the WAPPS-Hemo platform, incorporating data from 94 new patients between August 2022 and May 14, 2024. These updated models feature improved prediction accuracy, particularly for younger and older patients, ranging from 1.6 to 80 years. They are based on a comprehensive dataset of 169 patients and 884 one-stage factor activities. The models demonstrate very good precision and minimal bias in estimating terminal half-life and time to 2% (refer to the figure), when three factor activities are provided by the patient. Clinicians can continue to rely on these models to obtain individual pharmacokinetic estimates and utilize the clinical calculator for tailored dose regimen design.
Figure: Relative errors on time to 2% for Green Gene F and Green Mono
Korean Translation (한국어 번역)
WAPPS-Hemo는 그린진에프(Green Gene F) 및 그린모노(Green Mono)의 개선된 인구약동학 모델(population pharmacokinetic models)을 플랫폼에 반갑게 맞이합니다!
저희는 WAPPS-Hemo 플랫폼에 그린진에프(Green Gene F)와 그린모노(Green Mono) 모델의 개선판을 소개하게 되어서 기쁩니다. 개선된 모델에는 2022년 8월과 2024년 5월 14일 사이의 새로운 94명의 환자에서 얻은 데이터를 반영하였습니다. 이들 업데이트된 모델은 개선된 정확성(accuracy)을 특징으로 하는데, 특히 1.6세에서 80세, 소아 및 노인 환자를 대상으로 합니다. 포괄적으로 169명의 환자와 884개의 one-stage 방법으로 측정한 혈액응고 8인자 혈중 농도를 기반으로 합니다. 이 모델들은 환자로부터 세 개의 혈중 농도 값을 제공받았을 때, 말단 반감기(terminal phase half-life)와 혈중 농도 2%까지의 시간을 추정하는 것에서 대단히 양호한 정밀성(precision)을 나타냈으며, 최소한의 편향(bias)을 나타냈습니다 (도표 참고). 임상의들은 개인화된 약동학 추정을 얻기 위해 이들 모델을 근거로 할 수 있고 맞춤 용법 설계를 위해서 이 임상 계산기 사용을 계속할 수 있습니다.
도표: 그린진에프와 그린모노에 대한 2% 시간까지의 상대 오차
To activate the Plasminogen Module, go to the tab My Centre > Manage Factor Concentrates.
Then, in the table header, go to Add New Factor Concentrates, Plasminogen is now available.
Click on the concentrate dropdown menu (Advate is the first element of that dropdown menu) and select Plasminogen. Click on the assay dropdown menu (One Stage Coag. (PTT Based) is the first element of that dropdown menu) and select Chromogenic. Then, click on Add Factor Concentrate Specifics to add the Plasminogen as a new active concentrate and all the Plasminogen features related to it.
Note that if you Deactivate Plasminogen from the Active Factor Concentrates table, all the Plasminogen features will be disabled. To re-activate the feature, you only need to go to the Deactivated Factor Concentrates table and click on the button Activate in front of Plasminogen.
Benefix (one-stage)
We are pleased to announce the update of the Benefix model for use on the WAPPS-Hemo platform. This model was built on data from industry (24% of patients) along with data already collected through WAPPS-Hemo (76% of the patients). The two-compartment kinetic model uses fat-free mass as a covariate and involves data from 475 patients and 4511 one-stage assay factor activities. Patients were between 0.92 to 76.5 years and, based on model evaluations, the model is appropriate for use in estimating individual PK estimates on the WAPPS-Hemo platform. There is very good precision and almost no bias on estimates of terminal half-life (see figure) where three factor activities are provided.
We continuously update our population PK models using data submitted to WAPPS-Hemo along with trial data. Our goal is to ensure that individual PK estimates for patients are as precise as possible.
Adynovate (one-stage and chromogenic)
We are pleased to announce the update of the Adynovate one-stage and chromogenic models for use on the WAPPS-Hemo platform. These models are an update to the 2018 models to include more accurate predictions for younger WAPPS-Hemo patients (from 7 months old), which has been possible thanks to the HCT’s efforts to provide accurate input into the WAPPS-Hemo platform for over 6 years!
The two-compartment kinetic models use fat-free mass, age and (if provided) blood type as covariate; respectively involve 1992 one-stage and 888 chromogenic PK measurements from 698 and 233 hemophilia A patients. Based on model evaluations, the models are appropriate for use in Bayesian forecasting on the WAPPS-Hemo platform. There is very good precision and almost no bias on estimates of terminal half-life and time to 2% (see figure) where only 3 PK samples are provided.
Our goal is to ensure that individual PK estimates for patients from all ages are as precise as possible.
If you have any WAPPS-Hemo related research or news items you would like to share, please contact us
© 2025 Copyright WAPPS-Hemo